Norway Influenza Treatment Market Size & Outlook
Related Markets
Norway influenza treatment market highlights
- The Norway influenza treatment market generated a revenue of USD 81.0 million in 2024 and is expected to reach USD 89.6 million by 2030.
- The Norway market is expected to grow at a CAGR of 1.7% from 2025 to 2030.
- In terms of segment, oseltamivir phosphate was the largest revenue generating treatment in 2024.
- Baloxavir Marboxil is the most lucrative treatment segment registering the fastest growth during the forecast period.
Influenza treatment market data book summary
| Market revenue in 2024 | USD 81.0 million |
| Market revenue in 2030 | USD 89.6 million |
| Growth rate | 1.7% (CAGR from 2025 to 2030) |
| Largest segment | Oseltamivir phosphate |
| Fastest growing segment | Baloxavir Marboxil |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Peramivira, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate |
| Key market players worldwide | Novartis AG ADR, Roche Holding AG, BioCryst Pharmaceuticals Inc, Sanofi SA, GSK PLC, GSK PLC ADR, Viatris Inc, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Co Ltd, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, Norway accounted for 1.3% of the global influenza treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany influenza treatment market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 522.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Treatment Market Scope
Influenza Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| BioCryst Pharmaceuticals Inc | View profile | 531 | 4505 Emperor Boulevard, Suite 200, Durham, NC, United States, 27703 | https://www.biocryst.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Viatris Inc | View profile | 38000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | https://www.viatris.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Norway influenza treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to influenza treatment market will help companies and investors design strategic landscapes.
Oseltamivir phosphate was the largest segment with a revenue share of 28.15% in 2024. Horizon Databook has segmented the Norway influenza treatment market based on peramivira, zanamivir, baloxavir marboxil, oseltamivir phosphate covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Norway influenza treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway influenza treatment market databook
-
Our clientele includes a mix of influenza treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway influenza treatment market , including forecasts for subscribers. This country databook contains high-level insights into Norway influenza treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway Treatment - Influenza Treatment Market size, 2024 - 2030 (US$M)
Norway Influenza Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
